Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.72 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.67 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.67 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.67 |
| ▸ | ACE | P12821 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
| ▸ | FAP | Q12884 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361968 | 1.00 | DPP4 (0.72) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL30535978 | 1.00 | DPP4 (0.72) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL3715380 | 1.00 | DPP4 (0.72) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL2162356 | 0.94 | DPP4 (0.67) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL14982915 | 0.94 | DPP4 (0.67) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL2554245 | 0.92 | DPP4 (0.65) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL12285638 | 0.92 | DPP4 (0.71) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL1509250 | 0.91 | DPP4 (0.68) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL2554221 | 0.91 | DPP4 (0.63) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL2552198 | 0.91 | DPP4 (0.72) | DPP4DPP8DPP9DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409912-B2 | Process for the preparation of sitagliptin phosphate | CADILA HEALTHCARE LIMITED (IN) | 2016-08-09 | — | — | US | claimed |
| US-20150087834-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN PHOSPHATE | CADILA HEALTHCARE LIMITED (IN) | 2015-03-26 | — | — | US | claimed |
| EP-4151620-B1 | METHOD FOR PREPARING CHIRAL 4-ARYL-BETA-AMINO ACID DERIVATIVE | ZHEJIANG MED XINCHANG PHARM (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12534427-B2 | Method for preparing chiral 4-aryl-β-amino acid derivative | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2026-01-27 | — | — | US | disclosed |
| WO-2023181046-A1 | RECYCLABLE BIOCATALYTIC PROCESS FOR PREPARATION OF SITAGLIPTIN | IOL CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2023-09-28 | — | — | WO | disclosed |
| CN-116239491-A | Sitagliptin impurity compound I and preparation method thereof | 浙江永太科技股份有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20230174461-A1 | METHOD FOR PREPARING CHIRAL 4-ARYL-ß-AMINO ACID DERIVATIVE | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2023-06-08 | — | — | US | disclosed |
| US-20230174461-A1 | METHOD FOR PREPARING CHIRAL 4-ARYL-ß-AMINO ACID DERIVATIVE | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2023-06-08 | — | — | US | disclosed |
| US-20230174461-A1 | METHOD FOR PREPARING CHIRAL 4-ARYL-ß-AMINO ACID DERIVATIVE | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2023-06-08 | — | — | US | disclosed |
| EP-4151620-A1 | METHOD FOR PREPARING CHIRAL 4-ARYL-BETA-AMINO ACID DERIVATIVE | Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (CN) | 2023-03-22 | — | — | EP | disclosed |
| CN-113636950-B | Preparation method of chiral 4-aryl-beta-amino acid derivative | 浙江医药股份有限公司新昌制药厂 | 2023-01-17 | — | — | CN | disclosed |
| WO-2010078440-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES | CHIRAL QUEST, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| EP-1625847-B1 | Medical use of a tetrahydrotriazolo[4,3-a]pyrazine | MERCK SHARP & DOHME (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20100130504-A1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2010-05-27 | — | — | US | disclosed |
| US-20090192326-A1 | Preparation of sitagliptin intermediate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-30 | — | — | US | disclosed |
| US-20090192326-A1 | Preparation of sitagliptin intermediate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-30 | — | — | US | disclosed |
| WO-2009064476-A1 | PREPARATION OF SITAGLIPTIN INTERMEDIATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-22 | — | — | WO | disclosed |
| EP-1412357-B1 | BETA-AMINO TETRAHYDROIMIDAZO(1,2-A)PYRAZINES AND TETRAHYDROTRIAZOLO(4,3-A)PYRAZINES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1625847-A1 | Pharmaceutical composition comprising a tetrahydrotriazolo[4,3-a]pyrazine | Merck & Co., Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20040167133-A1 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192326-A1 | Preparation of sitagliptin intermediate | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
| US-12534427-B2 | Method for preparing chiral 4-aryl-β-amino acid derivative | OPRM1, SIGMAR1, GLRB | DPP4 1767/4885DPP8 3623/4885DPP9 4116/4885 |
| US-20230174461-A1 | METHOD FOR PREPARING CHIRAL 4-ARYL-ß-AMINO ACID DERIVATIVE | ENPEP, BCAT2, BCAT1 | DPP4 330/4885DPP8 1201/4885DPP9 1071/4885 |
| US-20040167133-A1 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 4/4885DPP9 6/4885 |
| US-20150087834-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN PHOSPHATE | DPP4, DPP9, SI | DPP4 1/4885DPP8 9/4885DPP9 2/4885 |
| US-20100130504-A1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.